Candel Therapeutics, Inc. (NasdaqGM: CADL)
Health Care · Biotechnology · US
$12.76
-2.82% today · +129.9% 1Y
Candel Therapeutics, Inc. (NasdaqGM: CADL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.00B and employs 55 people.
Over the last twelve months the share price has gained 129.9%, trading between 4.35 and 13.82.
Tweenvest scores Candel Therapeutics, Inc. across four factors: quality 28/100. Its strongest factor is quality.
CADL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.00B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.44
- Dividend yield
- —
- Beta (5Y)
- -0.50
- 52-week high
- $13.82
- 52-week low
- $4.35
- Avg volume (3M)
- —
- Shares outstanding
- 76.52M
- Employees
- 55
- Next earnings
- —
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
- Founded
- 2003
- Listed since
- Jul 27, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.50 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.55 | +0.28% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $144.90 | -0.83% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.37 | +0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $823.94 | -1.21% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $135.64 | -6.50% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.